GHK-Cu vs Epithalon

GHK-Cu is a copper-bound tripeptide studied in connective-tissue biology and specific topical skin and ulcer preparations. Epithalon, also called Epitalon, is AEDG, a four-residue peptide studied in telomere maintenance and aging-related models. GHK-Cu’s human skin results vary by preparation and setting; Epitalon’s telomere findings do not establish human rejuvenation. No direct trial identified here ranks their effects on skin aging or longevity.

Research reviewed October 15, 2026. Educational information only.

A copper complex and a separate four-residue peptide

GHK-Cu is glycyl-histidyl-lysine coordinated with copper(II). The copper-bound complex, copper-free GHK and a finished cream or gel are distinct experimental materials. A skin-care regimen can also contain ingredients beyond the peptide. Interpretation therefore begins with the preparation and comparison used in the particular report. Maquart et al. (1988).

Epithalon is a spelling variant of Epitalon, the sequence Ala-Glu-Asp-Gly, abbreviated AEDG. FDA separately describes its free base and acetate forms. Epithalamin is the pineal-gland extract discussed in older clinical reports, whereas AEDG is a defined four-residue peptide. The 266-person report of Epithalamin and Thymalin extracts cannot supply a human mortality effect for synthetic AEDG. FDA (2026), Khavinson et al. (2003).

The main differences

GHK-Cu research followed production of connective-tissue material

Maquart and colleagues exposed cultured fibroblasts, cells that make connective-tissue proteins, to GHK-Cu. Collagen production increased without a corresponding increase in cell number. That distinction means the result concerned what the cells produced, rather than simply a larger cell population. Maquart et al. (1988).

A separate rat experiment implanted mesh wound chambers and compared repeated local GHK-Cu exposure with saline. The collected chambers contained more collagen, glycosaminoglycans and other tissue material under effective conditions; collagen stimulation was about twice that of noncollagen proteins. Type I and III collagen RNA increased, while TGF-β RNA did not. A separate control tripeptide did not establish a comparable response. The experiment measured accumulation within an artificial wound environment, without measuring human wrinkle appearance or whole-body rejuvenation. Maquart et al. (1993).

GHK-Cu’s clinical findings depend on the skin problem and preparation

Miller and colleagues randomized post-laser skin-care regimens with or without GHK-Cu after resurfacing around the mouth. Thirteen patients completed twelve weeks. Computer analysis and blinded evaluators did not establish faster resolution of redness or an additional improvement in wrinkles or overall skin quality with the GHK-Cu regimen. Patient-rated overall skin quality favored that regimen (P=0.04). The small sample and difference between objective and questionnaire results leave the additional cosmetic benefit uncertain. Miller et al. (2006).

A separate randomized evaluator-blinded diabetic-ulcer study compared a specific GHK-Cu preparation, lamin Gel, with the gel base alongside standardized wound care. Median plantar-ulcer area closure was 98.5% with lamin Gel and 60.8% with the base (P<0.05). These percentages describe reduction in wound area, not the percentage of every patient whose ulcer completely healed. The primary abstract does not supply a complete analysis denominator for that estimate. Mulder et al. (1994).

The favorable diabetic-ulcer result does not erase a separate venous-ulcer trial. Among 86 evaluable completers, the tripeptide-copper cream did not establish better ulcer-size reduction than its inert cream base; silver sulfadiazine cream performed better than either. Differences in disease, wound care and formulations prevent combining these studies into one general GHK-Cu effect. None establishes effectiveness or safety of injecting GHK-Cu. Bishop et al. (1992).

Epitalon lengthened telomeres through different cellular processes

Telomeres are protective DNA–protein structures at chromosome ends. The 2003 Epithalon report described telomerase-related expression, enzyme activity and longer telomeres after adding the peptide to human fetal fibroblasts. These human-derived cells were outside the body, and the study did not measure health or lifespan in treated people. Khavinson et al. (2003).

Al-dulaimi and colleagues later compared untreated cells with Epitalon-exposed normal fibroblast and mammary epithelial cultures and two breast-cancer cell lines. The IBR.3 normal fibroblasts did not show telomere lengthening after four days. After three weeks, both normal fibroblast and mammary epithelial cultures had longer telomeres and increased telomerase activity. The cancer-cell lines showed telomere lengthening after four days without a corresponding clear increase in telomerase activity; the results instead implicated alternative lengthening of telomeres, or ALT, a different maintenance process. Figures 1–3 were replaced in a published correction and belong to this same study. Al-dulaimi et al. (2025), Al-dulaimi et al. (2026).

The different pathways are consequential because longer telomeres can describe different cellular states. The experiment did not establish that normal cells became healthier, that treated people lived longer or that a long-term cancer risk was absent. GHK-Cu’s collagen-production findings and Epitalon’s telomere measurements also address different physical changes, so their magnitudes cannot be compared as a common measure of anti-aging activity.

Animal survival and human biomarkers answer narrower questions

In a lifetime study of female Swiss-derived SHR mice, 54 animals receiving Epitalon were compared with 54 saline controls. The experiment did not establish an increase in mean lifespan. Mean lifespan among the last tenth of survivors rose 13.3%, and maximum lifespan rose 12.3%. These survival-tail findings should not be converted into a 12–13% increase in average lifespan, and the result does not estimate added years for people. Anisimov et al. (2003).

The human AEDG report measured melatonin-related biomarkers. FDA’s detailed account describes seventy-five women aged forty to fifty, mainly night-shift workers: thirty-five had age-normal urinary values and served as a reference, while forty with low values were assigned to AEDG or saline placebo for twenty days. The urinary melatonin-breakdown product rose 1.7-fold in the AEDG group and did not change with placebo; body-clock gene expression also changed. Blinding was unspecified, sleep outcomes were not measured and systematic safety data were not reported. These biomarkers remain distinct from the mortality claims in the older extract literature. Ivko et al. (2021), FDA (2026).

Clinical exposure and safety remain preparation-specific

The selected topical GHK-Cu reports measured local skin or wound outcomes and do not provide a validated blood half-life for an injected preparation. FDA’s current GHK-Cu concern specifically addresses injectable routes, citing limited human safety data and potential immune reactions from aggregation or peptide impurities. A topical study cannot resolve those injection-specific issues. FDA (2026).

For Epitalon, FDA describes a preliminary rabbit fluorescent-label distribution experiment whose tissue signal was not shown to specifically represent intact peptide. It identified no additional pharmacokinetic studies in that evaluation. The sources therefore supply no validated human blood-concentration curve or half-life. FDA also identifies substantial gaps in human safety and product characterization for the proposed substances. FDA (2026).

GHK-Cu has some formulation-specific human outcomes, including conflicting objective results across skin and ulcer settings. Epitalon has cell-maintenance, animal and limited human-biomarker findings. A fair clinical comparison would need the same population, a specified product and a shared health outcome. No such head-to-head comparison was identified in this selected review.

Frequently asked questions

Profiles and related reading

References

1. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS letters. 1988;238(2):343–346. doi:10.1016/0014-5793(88)80509-x. PMID:3169264.

   GHK-Cu increased collagen production in cultured fibroblasts without increasing cell number. The observation concerns protein production in a dish.

2. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, Monboisse JC, Chastang F, Birembaut P, Gillery P. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. The Journal of clinical investigation. 1993;92(5):2368–2376. doi:10.1172/JCI116842. PMID:8227353.

   GHK-Cu injected into rat wound chambers increased collagen and other matrix components relative to saline. A separate control tripeptide did not establish the same response.

3. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of facial plastic surgery. 2006;8(4):252–259. doi:10.1001/archfaci.8.4.252. PMID:16847171.

   In thirteen completers after laser resurfacing, a GHK-Cu skin-care regimen did not establish an objective advantage in redness, wrinkles or overall skin quality; patient-rated skin quality favored it.

4. Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 1994;2(4):259–269. doi:10.1046/j.1524-475X.1994.20406.x. PMID:17147644.

   In the diabetic-ulcer trial, median plantar-ulcer area reduction was 98.5% with the specified GHK-Cu lamin Gel preparation and 60.8% with the gel base alongside standardized wound care (P<0.05). These are wound-area reductions, without establishing benefit for every cosmetic or injectable formulation.

5. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of vascular surgery. 1992;16(2):251–257. doi:10.1067/mva.1992.37086. PMID:1495150.

   In a separate venous-ulcer trial with 86 evaluable completers, tripeptide-copper cream did not establish better ulcer-size reduction than the inert cream base; silver sulfadiazine performed better.

6. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of experimental biology and medicine. 2003;135(6):590–592. doi:10.1023/a:1025493705728. PMID:12937682.

   Epithalon induced expression and activity of telomerase, an enzyme that maintains chromosome ends, and produced longer telomeres, the protective DNA structures at chromosome ends, in cultured fetal fibroblasts. The donors were not treated and organism lifespan was not measured.

7. Al-dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26:178. doi:10.1007/s10522-025-10315-x.

   Normal-cell cultures developed longer telomeres, the protective structures at chromosome ends, and increased activity of telomerase, an enzyme that maintains those ends, after three weeks of Epitalon. Results from breast-cancer cells instead implicated alternative telomere lengthening after four days. Figures 1–3 were corrected.

8. Al-dulaimi S, Thomas R, Matta S, Roberts T. Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2026;27:1. Published online November 15, 2025. doi:10.1007/s10522-025-10326-8.

   The notice replaces incorrect Figures 1–3 for the same cell report and gives the corrected cell and time descriptions. It is not a second experiment.

9. Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193–202. doi:10.1023/a:1025114230714. PMID:14501183.

   In female Swiss-derived SHR mice, Epitalon did not establish an increase in mean lifespan, while maximum lifespan and survival among the last tenth increased. Each statistic describes a different part of the distribution.

10. Ivko OM, Linkova NS, Ilina AR, Sharova AA, Ruzhak GA. AEDG Peptide Regulation of the Expression of Human Circadian Rhythm Genes upon Accelerated Aging of the Pineal Gland. Advances in Gerontology. 2021;11(1):53–58. DOI: 10.1134/S2079057021010380.

    A limited human AEDG report describes increased urinary melatonin-metabolite output and altered body-clock gene expression. It did not establish improved sleep, physical function or longer life.

11. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. 2003;24(3–4):233–240. PMID:14523363.

    The 266-person older-adult report concerns Epithalamin and Thymalin extracts. Its mortality claims cannot be assigned to synthetic Epitalon or thymosin alpha-1.

12. U.S. Food and Drug Administration. Epitalon-related Bulk Drug Substances: Epitalon (Free Base) and Epitalon Acetate. Briefing material for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting.

    FDA distinguishes free base and acetate, identifies substantial human safety and product-characterization gaps and describes only preliminary rabbit fluorescent-label distribution information. Its assessment does not provide a validated human half-life.

13. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Official agency webpage accessed October 15, 2026.

    FDA identifies potential immune responses from aggregation and impurities in injectable GHK-Cu, with limited human safety data. Its Epitalon entry identifies similar product-quality concerns and insufficient human safety information for proposed routes.